Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
drugs
14
×
life sciences
national blog main
new york blog main
new york top stories
14
×
san francisco blog main
san francisco top stories
14
×
boston blog main
national top stories
san diego blog main
san diego top stories
boston top stories
clinical trials
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas top stories
wisconsin blog main
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
national
texas blog main
fda
indiana blog main
indiana top stories
biotech
cancer
gene therapy
merck
roche
startups
celgene
deals
eli lilly
investing
multiple myeloma
What
bio
drug
fda
roundup
medical
big
companies
decades
known
medicine
new
week
ago
american
annual
approved
ash
biotechs
blood
cancer
conference
diego
disease
drugs
gathering
largest
led
life
make
meeting
san
society
they’re
time
adapt
admits
advanced
ahead
alnylam
alzheimer’s
Language
unset
Current search:
drugs
×
" new york top stories "
×
" san francisco top stories "
×
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
4 years ago
Nobel Prize in Medicine Goes to 3 Who Showed How Cells Sense Oxygen Levels
@xconomy.com
4 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
4 years ago
PanTheryx Lands $50M to Use “First Milk” to Target Gut Microbiome
@xconomy.com
5 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
ASH 2018: Three Up, Two Down As The Big Blood Disease Meeting Rolls On
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision